Pershing Square Activist Presentation Deck

We Have Not Previously Invested in a Pharmaceutical Company The traditional pharmaceutical company's products are not durable, and growth is not predictable x Patent cliffs for major products x Huge investments in high-risk, low-return R&D to replace off-patent drugs x Price pressure in many segments x Bloated overhead and cost structures x Value-destroying acquisitions 9

View entire presentation